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Abstract
Background: Individuals with 1st degree relatives harboring an intracranial aneurysm (IA) are at an increased risk of IA,
suggesting genetic variation is an important risk factor.
Methods: Families with multiple members having ruptured or unruptured IA were recruited and all available medical
records and imaging data were reviewed to classify possible IA subjects as definite, probable or possible IA or not a case.
A 6 K SNP genome screen was performed in 333 families, representing the largest linkage study of IA reported to date.
A 'narrow' (n = 705 definite IA cases) and 'broad' (n = 866 definite or probable IA) disease definition were used in
multipoint model-free linkage analysis and parametric linkage analysis, maximizing disease parameters. Ordered subset
analysis (OSA) was used to detect gene × smoking interaction.
Results: Model-free linkage analyses detected modest evidence of possible linkage (all LOD < 1.5). Parametric analyses
yielded an unadjusted LOD score of 2.6 on chromosome 4q (162 cM) and 3.1 on chromosome 12p (50 cM). Significant
evidence for a gene × smoking interaction was detected using both disease models on chromosome 7p (60 cM; p ≤ 0.01).
Our study provides modest evidence of possible linkage to several chromosomes.
Conclusion: These data suggest it is unlikely that there is a single common variant with a strong effect in the majority
of the IA families. Rather, it is likely that multiple genetic and environmental risk factors contribute to the susceptibility
for intracranial aneurysms.
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Background
Subarachnoid hemorrhage due to the rupture of an intrac-
ranial aneurysm (IA) occurs in 16,000 to 17,000 persons
in the U.S. annually and nearly half of affected persons are
dead within the first 30 days. There are several important
factors which modulate the risk of SAH. The incidence of
SAH increases moderately with advancing age and it is the
only stroke subtype in which women have a higher age-
adjusted risk of SAH as compared to men [1]. Cigarette
smoking has consistently been identified as the most
important modifiable risk factor for SAH [2] with an aver-
age odds ratio of 3.1 [2,3]. In population-based and
cohort studies, 70–75% of persons with SAH have a prior
history of smoking and 50–60% are current smokers [2].
Hypertension accounts for an estimated 20% of all cases
of SAH secondary to IA [2]. African-Americans have twice
the age- and gender-adjusted risk of SAH as compared to
whites [2].
In addition to the importance of environmental risk fac-
tors, studies have also consistently demonstrated a genetic
component to the risk for SAH and IA. The risk for an SAH
in first degree relatives of an SAH patient has been
reported to range from 1.8 to as high as 6.6 times that of
an age matched control [2,4-7]. Studies have also shown
that first and second degree relatives of an SAH or IA
patient are at increased risk for an unruptured IA (8.7% –
13.9%, compared to estimated 1% in the general popula-
tion) [8-10].
Linkage analysis has been performed using both large
families with evidence of a Mendelian form of IA [11-14]
as well as large numbers of smaller families, typically with
two affected, genotyped individuals [15-18]. While link-
age to multiple regions of the genome has been reported,
evidence to several chromosomes, 1p36, 5q31, 7q11,
14q22, 17cen, 19q13 and Xp22, has been found in more
than one study. However, none of these studies consid-
ered environmental covariates when performing the link-
age analysis. Recently, association of two SNPs on
chromosome 9p21 has been reported in analyses consist-
ing of cases and controls from Iceland, the Netherlands
and Finland [19]. Analyses of each dataset individually as
well as jointly found that the G allele at rs10757278 is
associated with an approximately 1.29 fold increased risk
of an IA.
We recently completed a mid-study genetic analysis of a
sample of 192 multiplex IA pedigrees [20]. The greatest
evidence of linkage was found on chromosomes 4q, 7q,
8q and 12q. We performed analyses including the average
pack-years for the affected individuals in each family so as
to detect significant gene × smoking interactions. Three of
the four chromosomal regions (4, 7 and 12) all appear to
have greater effect in those families with the heaviest
smoking. Only on chromosome 8 did the inclusion of
smoking as a covariate not significantly strengthen the
linkage evidence, suggesting no interaction between the
loci in this region and smoking. We have now genotyped
the remainder of the sample and report linkage results in
the full sample of 333 multiplex IA pedigrees. We have
employed a series of complementary analyses allowing us
to model both the disease locus as well as gene × smoking
interactions. This approach increases the likelihood that
we will detect loci contributing to the risk of IA.
Methods
Subjects
Probands with an intracranial aneurysm (IA) were identi-
fied by 26 clinical centers (with 41 recruitment sites)
located throughout North America, New Zealand and
Australia [21]. The Familial Intracranial Aneurysm (FIA)
study was approved by the Institutional Review Boards/
Ethics Committees at all clinical and analytical centers
and recruitment sites. To be eligible, families were
required to meet one of the following criteria: 1) at least 2
living affected siblings; 2) at least 2 affected siblings, one
of whom is living and the other whose genotype could be
reconstructed through the collection of closely related, liv-
ing family members (i.e. spouse and children); 3) 3 or
more affected family members (e.g. cousin, uncle, aunt),
two of whom are alive and have living connecting rela-
tives; or 4) 3 or more affected family members, with one
living affected and at least one other affected relative
whose genotype could be reconstructed through the col-
lection of closely related, living family members. Exclu-
sion criteria included: 1) a fusiform-shaped IA of a major
intracranial trunk artery; 2) an IA which is part of an arte-
riovenous malformation; 3) a family history of polycystic
kidney disease, Ehlers Danlos Syndrome, Marfan's Syn-
drome, fibromuscular dysplasia or Moya-moya disease; or
4) failure to obtain informed consent from the patient or
family members.
Questionnaire data regarding demographics, environ-
mental risk factors, and family history of IA was obtained
from all family members. Blood was obtained for the iso-
lation of DNA. The first degree relatives of affected family
members who met study criteria for a higher risk of IA
were offered a free, study MRA with time-of-flight
sequences. The majority of MRAs were performed using a
1.5T (72.4%) MR imaging systems. The remainder were
diagnosed with 3.0T (21.9%), 4.0T (0.9%) or were identi-
fied with CTA (4.8%). Unfortunately, we can not address
the specificity and sensitivity of our MRA results because
our patients did not proceed to DSA for validation of the
non-invasive imaging tests. However, we note that MRA
screening for IAs is standard medical practice and studies
have reported MRA sensitivities and specificities between
90 and 97% for the detection of IAs [22,23]. Higher riskBMC Medical Genetics 2009, 10:3 http://www.biomedcentral.com/1471-2350/10/3
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was defined as: 1) 30 years of age or older and 2) either
had a 10 pack year history of current or former smoking;
or had an average blood pressure reading of ≥ 140 mm Hg
systolic or ≥ 90 mm Hg diastolic.
A Verification Committee reviewed all medical records
and the phone screen of the proband and family members
with a reported history of IA, SAH or intracerebral hemor-
rhage (ICH). Two neurologists who were members of the
Verification Committee independently reviewed the sub-
ject's records and determined whether the subject met all
the study inclusion and exclusion criteria. When the two
members disagreed, a third neurologist reviewed the data.
Each potential affected family member was ranked as def-
inite, probable, possible, or not a case (Table 1).
Genotyping
Genotyping was performed by the Center for Inherited
Disease Research (CIDR) using the 6 K Illumina array. A
total of 2,317 individuals from 394 families were geno-
typed by CIDR, with the samples sent at two intervals,
with results from the first sample set previously reported
[20]. All summary statistics reported herein are for the
combined sample. The error rate, based on paired geno-
types from 107 duplicate samples, was 0.0022%. The per-
centage of missing genotypic data was 0.24%
Extensive quality assessment of the genotypic data was
performed prior to initiating any linkage analysis. The
reported family structures were verified using the geno-
typic data [24] and, when necessary, pedigrees were
altered. Significant changes in pedigree structure (n = 12
families) or changes in the initial disease status following
phenotype verification (n = 49 families) resulted in the
removal of 61 families based on their lack of informative-
ness for linkage analysis.
Once the family structures were finalized, the remaining
marker data were reviewed in detail as a further step in
data validation. Marker allele frequencies were estimated
using PEDSTATS [25], which selected all Caucasian, non-
Hispanic (the primary single ethnic group – 85% of the
sample) unrelated individuals from which to estimate
marker allele frequency. Markers or individuals were
removed if: fewer than 90% of the individuals were geno-
typed for that marker (n = 28); fewer than 90% of the
markers were genotyped for that individual (n = 2). Mark-
ers that violated Hardy Weinberg equilibrium at p < 0.001
(n = 4) or with very low informativeness (minor allele fre-
quency < 0.05; n = 62) were removed from further analy-
sis. Mendelian errors in each family were reviewed and
genotypes were removed as needed to eliminate inconsist-
encies. Final genotypic quality control focused on remov-
ing any remaining genotypes that were likely to be
erroneous as it is unlikely that recombination events
would occur multiple times between adjacent markers
[26]. A total of 16,799 genotypes (0.15% of the total)
were removed in this final step.
Statistical Analysis
Including markers in high linkage disequilibrium (LD)
can inflate the evidence of linkage [27]; therefore, we
computed pairwise LD (using both D' and r2 statistics)
and in all cases where D' exceeded 0.70, we retained the
SNP with the highest minor allele frequency (i.e. the most
informative marker). Analyses were also performed to
assess the effect of employing r2 as the measure of LD. In
this instance, a threshold of r2 > 0.40 was employed to
identify SNPs with high LD. Results were similar using
both thresholds and final SNP selection was based on
results from the D' statistic [20].
The final analytic sample consisted of 333 families with
1,895 genotyped individuals. Of the 5,935 markers geno-
typed in common on the 6 K Illumina array by CIDR in
the two independent samples, genotypic data from 4,839
markers were included in the final genome screen. Two
models of disease were employed: 1) narrower disease
definition, which classified as affected only those individ-
uals who met the definite criteria (Table 1); and 2)
broader disease definition, which classified as affected
those individuals who met criteria for either definite or
probable IA (Table 1).
Table 1: Disease phenotypes
Classification Definition
Definite Medical records document intracranial aneurysm (IA) on angiogram, operative report, autopsy, or a non-invasive imaging report 
(MRA, CTA) demonstrates an IA measuring 7 mm or greater.
Probable Death certificate mentions probable intracranial aneurysm without supporting documentation or autopsy. Death certificate 
mentions subarachnoid hemorrhage (SAH) without mention of IA and a phone screen is consistent with ruptured IA (severe 
headache or altered level of consciousness) rapidly leading to death. An MRA documents an IA that is less than 7 mm but 
greater than 3 mm.
Possible Non-invasive imaging report documents an aneurysm measuring between 2 and 3 mm. SAH was noted on death certificate, 
without any supporting documentation, autopsy or recording of headache or altered level of consciousness on phone screen. 
Death certificate lists 'aneurysm' without specifying cerebral location or accompanying SAH.
Not a Case There is no supporting information for a possible IA.BMC Medical Genetics 2009, 10:3 http://www.biomedcentral.com/1471-2350/10/3
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We employed three complementary analytic methods to
evaluate the evidence of linkage. First, we performed
multipoint, model independent affected-relative pair
linkage analysis as implemented in Merlin [28]. Using a
multipoint approach allowed us to maximize the infor-
mation content at each position in the genome. This is
critical since each individual SNP has less power to detect
linkage than does each microsatellite markers which is
individually genetically more informative.
Second, we performed ordered subset analysis (OSA) to
test for gene × smoking interactions [29,30]. A quantita-
tive measure of cumulative smoking (pack-years) prior to
the diagnosis of an aneurysm was computed for each
affected individual in the genotyped families. Then, the
average number of pack-years for each family was calcu-
lated using only the affected individuals. This calculation
was performed separately for each of the two disease
model definitions (narrow and broad). Then, families
were ranked in descending order based on the average
pack-years for the family. Multipoint, model independent
affected-relative pair linkage analysis was then performed
for the subset of families in the first rank (i.e. lowest aver-
age pack years) using the computer program Genehunter
[30,31] and these linkage results were stored. The families
in the next rank were then added to the first-rank families,
and linkage analysis was performed again on this
expanded set of families. This process was repeated until
all families had been added to the analysis, at which point
the "ordered subset" of families with the maximum LOD
score (and the corresponding chromosomal position)
were identified. Statistical significance of any observed
increase in the maximum LOD score was determined
using permutation methods by randomly ranking fami-
lies. In the permutation procedure, the pack-years covari-
ate values were randomly assigned to the families without
replacement. The linkage analysis of ordered subsets was
performed on this replicate as for the observed data, and
the maximum LOD score on the chromosome was stored.
10,000 replicates were permuted in this fashion and a p-
value for significance of the OSA result (LOD score as a
function of smoking) was calculated by determining the
proportion of these replicates that met or exceeded the
observed OSA LOD score.
Given the extensive pedigree structures available for anal-
ysis, we proceeded to also perform parametric modeling.
Similar to the previous analyses, no family members were
classified as unaffected; all individuals not meeting dis-
ease criteria were coded as unknown. We avoided specify-
ing disease parameters; rather we utilized an approach
[32,33], which maximized the linkage evidence in each
chromosomal region by estimating the disease parame-
ters. This is often called a maximized LOD score (MOD
score) and requires an upward adjustment in the typical
significance thresholds employed in linkage analysis,
since the disease parameters are being estimated and thus
the test is fitting one additional parameter.
Results
The narrower disease model included in the analysis 290
families consisting of 1,647 genotyped samples. There
were 705 family members with definite IA. The broader
disease model included 333 families with 1,895 geno-
typed samples, with 866 members meeting criteria for def-
inite or probable IA (Table 2). Family structures varied
widely and included both two generational and multigen-
erational pedigrees, with the largest pedigrees spanning
five generations. Typically, the affected individuals were
identified in either a single generation or in up to three
generations. Overall, ~38% of the pedigrees were two gen-
erational, with most of these consisting of affected sib-
lings. Another ~44% were three generational pedigrees
with affected individuals in one, two or all three genera-
tions. Sixteen percent of pedigrees had four generations
and the remaining 2% were five generations. Note that
samples were not obtained in all generations; rather, these
summary statistics describe the pedigree structure
required to link genotyped individuals at-risk for disease.
MRA was offered to the subset of first degree relatives of
affected individuals who also had a higher risk of IA due
to age and smoking or hypertension. A study MRA was
completed in 380 individuals from 182 different families.
The average number of individuals who completed a
study MRA in each family was 1.14; however, as might be
expected the number of study MRAs in each family varied
(range 0–8), and was influenced by the number of living
members who met the high risk criteria.
Genome-wide model independent linkage analysis
employing both the narrower and broader disease model
did not detect any chromosomal region with a LOD score
greater than 1.5 (Table 3; Figure 1). We then performed
the model independent linkage analysis using only the
283 families reporting themselves to be Caucasian as well
as not Hispanic. When employing the narrower disease
model, despite the smaller dataset, the possible evidence
of linkage to chromosome 7 increased to a LOD = 1.75
near the marker rs441534. In all other regions, the evi-
dence for linkage was slightly lower or unchanged. Simi-
larly, when performing analyses with the broader
definition, the LOD scores were slightly lower due to the
smaller sample size, but otherwise relatively unaltered.
Analyses were then performed to detect evidence for a
gene × smoking interaction (Table 3). Evidence of a gene
× smoking interaction was observed on chromosome 3p
(Narrower model: 80 cM; p = 0.001; Broader model: 85
cM; p = 0.001) and two regions on chromosome 7, 7p14.1BMC Medical Genetics 2009, 10:3 http://www.biomedcentral.com/1471-2350/10/3
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(Narrower model: 63 cM; p = 0.001; Broader model: 60
cM; p = 0.01) and 7q36.2 (Narrower model: 188 cM; p =
0.008; Broader model: 167 cM; p = 0.01). However, for
chromosome 3p and 7q, a small proportion of families
provided the evidence for the interaction (typically 5–
13% of the families). Therefore, since only a small propor-
tion of the dataset contributed to these linkage results,
these results are more likely to be spurious. We therefore
focused our attention on the evidence of a gene × smoking
interactions on chromosome 7p, which is supported by
nearly a third of the sample, the 31% of families with the
highest average rate of smoking in the affected subjects.
Finally, we performed parametric linkage analysis using
the two disease definitions and maximized the disease
parameters to obtain the greatest evidence for linkage. We
identified two chromosomal regions of interest (Table 3).
On chromosome 4q (162 cM), an unadjusted LOD score
Table 2: Sample demographics
Narrower Disease Model Broader Disease Model
Number of families 290 333
Number of genotyped individuals 1,647 1,895
% Caucasian, nonhispanic 84.5% 84.1%
Individuals meeting criteria for IA
Total Number 705 866
% Female 76 75
Average age at diagnosis (years) 49.2 49.7
% current (prior) smoker1 47.9 (27.2) 48.4 (29.4)
Average pack years of smoking1 28.6 29.8
% reporting hypertension1 43.8 45.0
% reporting > 2 standard drinks per day1 9.8 9.6
Individuals not meeting criteria for IA
Total Number 1025 1181
% Female 58 58
% current (prior) smoker2 28.6 (32.1) 27.3 (32.9)
Average pack years of smoking2 24.3 24.1
% reporting hypertension2 33.7 33.2
% reporting > 2 standard drinks per day2 8.9 9.1
# of all FIA family members undergoing MRA 318 380
% positive MRA (definite or probable) 2.8 7.6
1 Data for the individuals with an IA is at the time of the identification of the aneurysm.
2 Data for the individuals without an IA is at the time the questionnaire was completed.
Table 3: Summary of linkage analyses
Chromosome1/
Position2
Model Independent Linkage Analysis
LOD score
Ordered Subset Analysis
Gene × smoking LOD score (p-
value3)
Parametric Linkage Analysis
LOD score
Narrower4 Broader5 Narrower4 Broader5 Narrower4 Broader5
4q32.3/160–162 
cM
0.5 1.3 NS6 NS 1.6 2.6
7p14.1/60–63 cM 0.7 0.6 4.1 (0.001) 3.2 (0.01) 0.4 0.7
7q22.3/116–118 
cM
1.5 1.3 NS NS 1.6 1.3
12p12.3/35–50 cM 1.4 1.4 NS NS 2.4 3.1
1 Cytogenetic position of the maximum LOD score
2 Location of the maximum LOD score on the deCode map
3 Permutation testing was performed to obtain p-values associated with the increase in LOD score observed when modeling gene × smoking 
interaction when compared with modeling for genetic effects only.
4 Narrower disease model (n = 290 families)
5 Broader disease model (n = 333 families)
6 Not significantBMC Medical Genetics 2009, 10:3 http://www.biomedcentral.com/1471-2350/10/3
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Results of multipoint, model independent linkage analysis Figure 1
Results of multipoint, model independent linkage analysis. The X-axis depicts the various chromosomes across the 
genome with chromosome 1 at the far left and the X chromosome at the far right. The Y-axis indicates the LOD score at the 
various chromosomal positions across the genome. A. Narrower disease definition (n = 290 families); B. Broader disease defi-
nition (n = 333 families).BMC Medical Genetics 2009, 10:3 http://www.biomedcentral.com/1471-2350/10/3
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of 2.6 was obtained with the best fitting disease parame-
ters including a rare disease allele (0.7% frequency) and
reduced penetrance for both the heterozygotes (~25%)
and homozygotes (~40%). On chromosome 12p (50 cM)
an unadjusted LOD score of 3.1 was obtained. In this
region, the maximal LOD score was obtained with a more
common disease allele (4% frequency), and very low pen-
etrance for heterozygotes (~5%) and modest penetrance
for homozygotes (~50%).
Discussion
We have performed a genome screen in the largest sample
of multiplex IA families ever studied. With over 5,000
SNPs genotyped, we performed a series of complementary
analyses to detect genetic factors which increase the sus-
ceptibility for IA. One of the major conclusions to be
drawn from the multifaceted analyses performed in this
study is that no chromosomal region provided strong evi-
dence of linkage to IA. The sample size included in this
study is relatively large and many of the families are quite
extensive. Given the strong evidence regarding the herita-
bility of IA, we interpret the modest results from the anal-
yses of this large sample to suggest two possible
hypotheses. The first hypothesis would postulate that
multiple loci, rather than a single chromosomal region,
contribute to the risk of IA and that several of these loci
may have important interactions with other genes or envi-
ronmental factors such as smoking. In this scenario, the
presence of interactive effects rather than strong main
effects, decreases the ability to detect linkage and also sug-
gest that the combination of many different sets of loci
may modify the risk for IA. The second hypothesis would
be that there are some genes of strong effect, but that any
one of these genes segregates in such a small proportion
of the families that we do not have the power to detect
their individual effects.
Despite the overall lack of a strong linkage signal with our
multi-pronged approach, we were able to identify several
chromosomal regions of potential interest. The region on
chromosome 4q identified in this study was also detected
in the previous analysis of the first portion of this dataset
[20]. A nearby region (at 140 cM) was also reported linked
in a sample of 119 families with at least two members
with an abdominal aortic aneurysm [34]. A region on
chromosome 12p was also identified. We previously
detected evidence of linkage to chromosome 12 in a sub-
set of the families analyzed in the current dataset [20].
Importantly, in the previous study, possible evidence of
linkage was found in a region on chromosome 12q21.33
(at 102 cM). Analyses to detect gene × smoking interac-
tion found the greatest effect of this locus in families with
the heaviest rates of smoking. The data we report in this
enlarged sample would appear to have detected a com-
pletely distinct locus on chromosome 12p, more than 50
cM proximal to the previously reported locus. We also
found some possible support for linkage to chromosome
7q22. A region on 7p14 provided the strongest evidence
for a gene × smoking interaction. Approximately one third
of the families, all heavy smokers, contributed to this
interaction. Thus, as we have enlarged the sample from
192 families to 333 families, we have continued to detect
linkage to chromosome 4q; however, there are several
other regions identified in the earlier study that were not
detected in the new analyses. There are several possible
reasons for this. The first is that the initial finding may
have been a false positive result and with the larger sample
size, we have greater power to detect true linkage. Another
possibility is that with the addition of over 100 new fam-
ilies, we have not included the same genetic risk factors
that were segregating in the initial group of families. It is
impossible to test this hypothesis; however, evidence
against this possibility is that families continue to be
recruited at the same sites and there is no obvious differ-
ence in the clinical findings or family history of the previ-
ously analyzed families and the newly analyzed families.
With these caveats, the primary advantage of the new
analysis is the much larger sample of families included in
the analysis, providing greater power to detect linkage.
The analyses performed in this large dataset did not detect
evidence of linkage to the chromosomal regions identi-
fied in more than one previous study: 1p36, 5q31, 7q11,
14q22, 17cen, 19q13 and Xp22. Our study, as well as pre-
vious linkage studies, did not detect evidence of linkage to
chromosome 9p21 [19] which was recently reported asso-
ciated to both IA and abdominal aortic aneurysm in
multi-ethnic samples (odds ratio of 1.29). Linkage stud-
ies, even one with over 300 families as this one has, does
not have the power to detect a locus with such a small
effect size, even if the SNP allele is relatively common, as
is the case with the high risk G allele of rs10757278.
We have explored the effect of gene × smoking interac-
tions in the FIA Study sample. As shown in Table 2, nearly
three quarters of the individuals meeting criteria for IA are
either current or past smokers. Therefore, this study has far
greater power to detect loci which interact with smoking
and quite limited power to detect loci that act only in
those individuals who do not smoke. For this reason, we
focused our interaction analyses toward the identification
of loci having their greatest effect in families with greater
smoking (i.e. higher pack years).
This study has several advantages. First, a large number of
multiplex IA families were ascertained through an interna-
tional consortium. This series of families has the power to
detect loci with strong to moderate genetic effects. Second,
uniform collection and review of clinical and environ-
mental exposure data was performed improving theBMC Medical Genetics 2009, 10:3 http://www.biomedcentral.com/1471-2350/10/3
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power to detect genetic effects. Third, individuals within
the families at increased risk for an IA were offered MRA,
allowing us to further improve the power to detect linkage
by increasing the number of affected individuals in the
pedigree. Fourth, a 6 K SNP screen was performed reduc-
ing the likelihood that any region of the genome would be
uninformative and again maximizing the power to detect
linkage anywhere in the genome.
This study also had potential limitations. In order to
accrue the large number of families analyzed in this data-
set, families were recruited from a wide geographic region
across two continents. This could result in a heterogene-
ous sample with many different susceptibility genes segre-
gating within the sample. Some other studies have
focused on only one or a small number of families, typi-
cally from the same geographic or ethnic origin. This more
limited approach would likely limit the number of differ-
ent susceptibility genes segregating in the sample and
could increase the power to detect the genes contributing
to IA in that small number of families. To reduce the
potential heterogeneity in the dataset, we performed our
model-independent linkage analysis in a more limited
dataset consisting of only those families reporting them-
selves to be Caucasian and not Hispanic. Results were rel-
atively unaltered suggesting that the linkage findings were
primarily supported by the Caucasian non-Hispanic fam-
ilies which represent the vast majority of our study fami-
lies. Another limitation of this study may be a bias
introduced by offering a study MRA to only higher risk
family members. For cost savings, a study MRA was only
offered to study participants who had a critical risk factor
(smoking, hypertension) that increased the likelihood
that an unruptured aneurysm might be identified. There-
fore, it is possible that aneurysms detected by study MRA
may be more likely to be the result of a critical environ-
mental exposure (smoking) rather than genetic factors.
However, given the small number of positive MRA which
met criteria for Probable or Definite criteria (< 9%), it is
unlikely that the statistical results would be significantly
biased by the inclusion of a small number of potentially
environmentally influenced cases.
The use of dense SNP marker maps, such as those cur-
rently available for genome wide association studies, may
be an important tool needed to identify the genetic risk
factors influencing IA susceptibility. We are currently per-
forming a case control study I the FIA sample with a dense
set of SNP markers to improve our power to detect com-
mon risk alleles with moderate effect.
Conclusion
These data suggest it is unlikely that there is a single com-
mon variant with a strong effect in the majority of the IA
families. Rather, it is likely that multiple genetic and envi-
ronmental risk factors contribute to the susceptibility for
intracranial aneurysms.
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